PRDM9 and nonpapillary renal cell carcinoma: EZH2, a histone methyltransferase catalyzing H3K27 trimethylation (H3K27me3), has been shown to promote stemness, EMT and Sunitinib resistance in ccRCC and other tumors (42–44).